Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.44M 2.27M 2.08M 3.91M 266M 3.97M 26.97M 10.54M 131M 10.41M 10.19M 454M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.73M 8.12M 7.46M 14.01M 952M 14.19M 96.55M 37.71M 470M 37.26M 36.46M 1.62B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 70 01/03/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%+5.03%+56.71%+66.69% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-2.05%-2.14%+2.93%+413.38% 23.18B
+1.97%-1.16%-19.24%-13.25% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+2.09%+28.01%-27.56% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+0.79%+0.50%+25.73%+184.74% 13.92B
Average +0.56%+1.62%+42.32%+177.10% 26.68B
Weighted average by Cap. -0.06%+1.93%+40.37%+137.85%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 7.01 0.1 0.71 0.28 3.46 0.27 0.27 11.97 0.14 0.12 0.11 0.1 0.19 12.98 0.19 1.32 0.51 6.41 0.51 0.5 22.15
Net income -3.1M -2.73M -2.54M -2.33M -4.38M -298M -4.44M -30.2M -11.8M -147M -11.66M -11.4M -508M -18.47M -16.24M -15.12M -13.88M -26.07M -1.77B -26.42M -180M -70.19M -875M -69.35M -67.86M -3.02B
Net Debt 7.1M 6.24M 5.81M 5.33M 10.01M 680M 10.14M 69.01M 26.95M 336M 26.63M 26.06M 1.16B 7.15M 6.29M 5.85M 5.38M 10.09M 686M 10.23M 69.58M 27.17M 339M 26.85M 26.27M 1.17B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-